Recently Featured

Health execs persevere in new policy landscape

June 3, 2026
Despite a prolonged period of policy uncertainty in the U.S.—and the ripple effects across the global life sciences and healthcare industries—executives at health companies are still seeing opportunities amid the tumult. This resilience is indicative of a broader trend where industry leaders are adapting to shifting regulations and market dynamics while continuing to prioritize innovation…

PSA Screening for Prostate Cancer Reduces Disease-Specific Deaths, New Review Shows

June 3, 2026
Prostate-specific antigen (PSA) blood testing is likely to reduce the risk of death from prostate cancer, found a new review published on Thursday by an influential international science research organization — a shift in medical evidence that could encourage wider use. The Cochrane review’s first author, Juan Franco from Heinrich Heine University Düsseldorf in Germany,…

Supreme Court preserves access to widely used abortion pill, while lawsuit plays out

June 3, 2026
WASHINGTON — The Supreme Court on Thursday preserved women’s access to a drug used in the most common method of abortion, rejecting lower-court restrictions while a lawsuit continues. This ruling ensures that mifepristone, the medication in question, remains available to women seeking abortions, allowing them to obtain it at pharmacies or through the mail without…

FDA Enhances Access to Regulatory References for Drug Development

June 2, 2026
The FDA has launched a new initiative aimed at improving access to regulatory references pertinent to drug development. This resource encompasses critical information across various stages of the drug lifecycle, including applications, submissions, manufacturing, quality assurance, safety protocols, and labeling requirements. By centralizing these references, the FDA seeks to streamline the regulatory process for pharmaceutical…

Ongoing Cases